New TB vaccine candidate enters human testing

NCT ID NCT07647107

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: PT Bio Farma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental tuberculosis vaccine called Lipovaxin in healthy adults aged 18 to 40 in Indonesia. The vaccine is given as two shots, 28 days apart, and compared to a placebo. The main goals are to check if the vaccine is safe and whether it triggers an immune response against TB.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lipovaxin tuberculosis vaccine
What this could lead to: If successful, this could pave the way for a new vaccine to prevent tuberculosis, a major global health threat.
What could go wrong: This is an early Phase 1 trial with only 60 participants, focused on safety and immune response, not yet on preventing disease. The vaccine may not produce strong enough immunity or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TB INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

latent tuberculosis infection tuberculosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TB INFECTION TUBERCULOSIS

Contacts and locations

Locations

Cipto Mangunkusumo Hospital, Jl. Pangeran Diponegoro No. 71, Kenari, Jakarta Pusat, DKI Jakarta.

Jakarta Pusat, DKI Jakarta, 10430, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.